Equity Overview
Price & Market Data
Price: $5.51
Daily Change: +$0.28 / 5.08%
Daily Range: $5.32 - $5.51
Market Cap: $338,134,816
Daily Volume: 2,345
Performance Metrics
1 Week: 7.17%
1 Month: -1.88%
3 Months: -20.88%
6 Months: -13.55%
1 Year: 287.4%
YTD: -20.52%
Company Details
Employees: 37
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.